Blockchain Registration Transaction Record

Scinai Immunotherapeutics to Showcase Milestones at BIO 2025

Scinai Immunotherapeutics announces CEO's participation in BIO 2025, showcasing CDMO growth and nanobody pipeline progress. Read more on their strategic milestones.

This news is significant for investors and stakeholders in the biopharmaceutical industry, as it highlights Scinai Immunotherapeutics' progress and financial health. The company's participation in the BIO International Convention 2025 and its recent funding achievement underscore its potential for growth and innovation in developing treatments for diseases with unmet medical needs. Additionally, Scinai's CDMO business growth and revenue targets provide a glimpse into the company's strategic direction and its role in supporting early-stage biotech companies, making it a key player to watch in the evolving biotech landscape.